1. In Vivo
  2. >>Global Vision

Market Decapitalization

An overview of average market capitalization decline among European quoted biotech companies in the year beginning September 2001.

The average market capitalization of the top quoted biotechnology companies in each of the various European markets declined by between 20% and 45% in the year beginning September 1, 2001. (Average market cap in each territory is calculated by averaging the share price of the highest cap biotech companies in that territory and multiplying by the total number of outstanding shares, see details on chart.) Although the average decrease in market cap among the 16 European companies surveyed is 44.5%, there are noticeable geographic variations.

The German market has been the hardest hit, with a mean 55% loss in market cap, reflecting the relative immaturity...

Welcome to In Vivo

Create an account to read this article

Already a subscriber?

More from Global Vision

By The Numbers: Phase III Trials In China Skyrocket While Phase I Falls To Earth

 
• By Mainbayar Badarch

China has rapidly expanded its clinical trial footprint since 2015, driven by regulatory reforms and increased investment in pharma R&D. By 2023, it matched the US in trial volume. Oncology leads, but biologics are leading in momentum.

Navigating the GLP-1 Opportunity In China: Strategic Imperatives For Western Pharma

 
• By Jo Shorthouse

The Chinese appetite for GLP-1s is noticeable. While the market opportunity for western pharma is huge, so are the strategic market access challenges, though not unsurmountable, L.E.K. Consulting told In Vivo.

Can Italy Shake Off Its Reputation And Become A Premier Hub For Biotech?

 
• By Barnaby Pickering

Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By Jung Won Shin

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

More from In Vivo

Deals Shaping The Industry, July 2025

An interactive look at pharma, medtech and diagnostics deals made during July 2025. Data courtesy of Biomedtracker.

By The Numbers: Phase III Trials In China Skyrocket While Phase I Falls To Earth

 
• By Mainbayar Badarch

China has rapidly expanded its clinical trial footprint since 2015, driven by regulatory reforms and increased investment in pharma R&D. By 2023, it matched the US in trial volume. Oncology leads, but biologics are leading in momentum.

Pharma’s Space Trails Entering Transformative Era

 
• By Anju Ghangurde

Merck and Lilly are among the leading pharma players using space-based research to power drug development. From reusable satellites to process drugs in low earth orbit to biomanufacturing labs experts discuss R&D opportunities in the starry canvas above.